TAC01-HER2 (Auto) is under clinical development by Triumvira Immunologics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAC01-HER2 (Auto)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TAC01-HER2 (Auto) overview

TAC-01HER2 is under development for the treatment of HER2-positive solid tumors including breast cancer, pancreatic cancer, lung cancer, endometrial cancer, ovarian cancer, colorectal cancer and gastric cancer. It is administered by intravenous route. The drug candidate is developed based on TAC technology where T-cells are engineered to express T-cell Antigen Coupler (TAC) receptor. It acts by targeting cells expressing HER2 (human epidermal growth factor receptor) and cells expressing Claudin 18.2 (CLDN18.2). It was also under development for the treatment of glioblastoma multiforme, ovarian cancer, and sarcoma.

Triumvira Immunologics overview

Triumvira Immunologics (Triumvira) is a biopharmaceutical company involved in developing novel cancer therapies. The company uses chimeric antigen receptors and engineered T-cell receptors for development of the therapies. Triumvira is involved in investigation of mechanism in which TAC directs the engineered T-cells to target antigen and activates the T-cells after binding with antigen. The company’s product pipeline include TAC01-HER2 and TAC02-HER2 for autologous and allogenic solid tumors which are in initial stages of development. It also investigates on B cell maturation antigen (BCMA) for treatment of Multiple myeloma which is currently in initial phases of clinical trials. The company operates research facility in Hamilton, Ontario, Canada. Triumvira is headquartered in Austin, Texas, the US.

For a complete picture of TAC01-HER2 (Auto)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.